155 related articles for article (PubMed ID: 12523458)
1. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Antoniou T; Park-Wyllie LY; Tseng AL
Pharmacotherapy; 2003 Jan; 23(1):29-43. PubMed ID: 12523458
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
Squires K; Pozniak AL; Pierone G; Steinhart CR; Berger D; Bellos NC; Becker SL; Wulfsohn M; Miller MD; Toole JJ; Coakley DF; Cheng A;
Ann Intern Med; 2003 Sep; 139(5 Pt 1):313-20. PubMed ID: 12965939
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate.
Chapman T; McGavin J; Noble S
Drugs; 2003; 63(15):1597-608. PubMed ID: 12887265
[TBL] [Abstract][Full Text] [Related]
6. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Margot NA; Isaacson E; McGowan I; Cheng A; Miller MD
J Acquir Immune Defic Syndr; 2003 May; 33(1):15-21. PubMed ID: 12792350
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
8. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
9. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Margot NA; Isaacson E; McGowan I; Cheng AK; Schooley RT; Miller MD
AIDS; 2002 Jun; 16(9):1227-35. PubMed ID: 12045487
[TBL] [Abstract][Full Text] [Related]
10. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
Guo Y; Fung HB
Pharmacotherapy; 2004 Aug; 24(8):1089-94. PubMed ID: 15338857
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir disoproxil fumarate.
Kumar A
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887267
[No Abstract] [Full Text] [Related]
12. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir disoproxil fumarate.
Antoniou T
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
[No Abstract] [Full Text] [Related]
14. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir-related nephrotoxicity in HIV-infected patients.
Barrios A; García-Benayas T; González-Lahoz J; Soriano V
AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
[No Abstract] [Full Text] [Related]
17. Summaries for patients. Treatment for resistant HIV-1 infection.
Ann Intern Med; 2003 Sep; 139(5 Pt 1):I22. PubMed ID: 12965954
[No Abstract] [Full Text] [Related]
18. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
McColl DJ; Margot NA; Wulfsohn M; Coakley DF; Cheng AK; Miller MD
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1340-50. PubMed ID: 15483463
[TBL] [Abstract][Full Text] [Related]
19. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
[TBL] [Abstract][Full Text] [Related]
20. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
Nelson M; Portsmouth S; Stebbing J; Atkins M; Barr A; Matthews G; Pillay D; Fisher M; Bower M; Gazzard B
AIDS; 2003 Jan; 17(1):F7-10. PubMed ID: 12478090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
